<DOC>
	<DOCNO>NCT02721069</DOCNO>
	<brief_summary>This 12 month safety study evaluate safety repeat dose NRL-1</brief_summary>
	<brief_title>Repeat Dose Safety Study NRL-1 Epilepsy Subjects</brief_title>
	<detailed_description>This Phase 3 , repeat dose , open-label , safety study Epilepsy subject frequent breakthrough seizure Acute Repetitive Seizures ( ARS ) . NRL-1 administer need treat bout seizures 12-month period time . Doses define 5 mg , 10 mg , 15 mg , 20 mg base subject 's body weight . A diary use record seizure NRL-1 administration .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>1 . Male female subject age 6 65 year , inclusive . 2 . Written inform consent participate study . 3 . Subject clinical diagnosis Epilepsy stable regimen antiepileptic medication , still experience bout seizure ( e.g . frequent break seizure Acute Repetitive Seizures [ ARS ] ) , , opinion Investigator , may need benzodiazepine intervention seizure control least 1 time month average . 4 . Subject qualify caregiver medical professional available administer study medication event seizure . 5 . Subjects either partial generalized Epilepsy motor seizures seizure clear alteration awareness . 6 . Female subject childbearing potential , defined menstrual cycle surgically sterile less two ( 2 ) year postmenopausal , must complete pregnancy screen agree utilize one follow form contraception trial 21 day last dose study drug : abstinence , hormonal ( oral , transdermal , implant , injection ) , barrier ( condom , diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( six month minimum ) . Subjects must use method least one ( 1 ) month prior start study . 7 . No clinically significant abnormal finding medical history , physical examination electrocardiogram ( QTcF &lt; 450 msec male QTcF &lt; 470 msec female ) . 8 . Subjects caregiver must agree return study site study visit must willing comply require study procedure . 1 . A history clinically significant gastrointestinal , renal , hepatic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease , condition , opinion Investigator , would jeopardize safety subject . 2 . Subject significant traumatic injury , major surgery open biopsy within 30 day prior study screen . 3 . Subjects active major depression past suicide attempt , Suicidal Ideation 3 , 4 , 5 Suicidal Behavior Lifetime use ColumbiaSuicide Severity Rating Scale ( CSSRS ) . The pediatric CSSRS use subject age 6 11 . The adult C SSRS use subject 12 great year age . 4 . A history allergic adverse response diazepam comparable similar product . 5 . Participation clinical trial protocol DIAZ.001.04 within 30 day prior Day 0 . Participation observational ( noninterventional ) study exclude long scheduling conflict study . 6 . Positive serum pregnancy test ( ÃŸhCG ) screen subject age 12 great . 7 . Positive blood screen Human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HbSAg ) , Hepatitis C , positive urine screen alcohol drug abuse , except marijuana use medical reason . When marijuana use medical reason opinion investigator , consider drug abuse patient enrol even marijuana metabolite urine reveal positive .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Epilepsy</keyword>
</DOC>